- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00634140
The Influence of Ezetimibe on Gallbladder Function
Te Influence of Ezetimibe on Gallbladder Function
Ezetimibe is a drug which inhibits the absorption of both dietary and biliary cholesterol in the small intestine. Ezetimibe has been approved for use in humans to lower serum cholesterol.
The primary aim of this study is to determine if ezetimibe normalizes resting and residual volume in patients with chronic acalculous cholecystitis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gallbladder disease continues to be a major healthcare problem in the United States with more than 750,000 cholecystectomies being performed each year. In the last decade, the proportion of elective cholecystectomies performed for chronic acalculous cholecystitis has more than doubled. During this same time, obesity has reached epidemic proportions. In addition, obesity-induced visceral steatosis is known to cause a local inflammatory process resulting in organ dysfunction, with nonalcoholic steatohepatitis being a well established example of this phenomenon. Previous data from our lab also have shown that both congenital and diet-induced obesity result in cholecystosteatosis, an increase in gallbladder wall fats accompanied by altered gallbladder motility and absorption. This phenomenon also has been documented in humans, with patients with chronic acalculous and/or calculous cholecystitis having increased gallbladder fat than nondiseased controls.
Ezetimibe is a drug which inhibits the absorption of both dietary and biliary cholesterol in the small intestine. Ezetimibe has been approved for use in humans to lower serum cholesterol. Moreover, ezetimibe has been shown to ameliorate hepatic steatosis and cholesterol gallstone formation in animal models. Previous data from our lab have documented that ezetimibe lowers serum cholesterol, prevents biliary crystals and ameliorates cholecystosteatosis in lean mice fed a high fat diet. However, the influence of ezetimibe on gallbladder motility, absorption and accumulation of toxic fats, metabolites, cytokines and chemokines, cholecystosteatosis, have not been studied in humans. Therefore, the aims of this study are 1) to determine if ezetimibe normalizes resting and residual volume in patients with chronic acalculous cholecystitis, 2) to determine if ezetimibe normalizes gallbladder ion flux in patients with chronic acalculous cholecystitis and 3) to determine if ezetimibe normalizes gallbladder absorption/secretion modulators as well as gallbladder fat, cytokines and chemkines.
Subjects with typical biliary pain and or ejection fraction less than 30% on a HIDA scan will be identified. Patients will then be randomized with one group given ezetimibe and the other group given placebo. All subjects will have gallbladder ultrasound studies to determine volume before and after a standardized fatty meal both before starting ezetimibe or placebo and after 4 weeks. A cholecystectomy will then be performed. In addition, pieces of the gallbladder taken at cholecystectomy will be analyzed for ion flux, as well as absorption/secretion modulators and accumulation of toxic fats, metabolites, cytokines and chemokines.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with typical biliary pain and ejection fraction <30% on a HIDA scan.
- Must be > 18 years of age.
Exclusion Criteria:
- Subjects with gallstones seen on HIDA.
- Subjects on statin medication
- Subjects with known allergies to ezetimibe.
- Subjects who are pregnant or breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
ezetimibe
|
ezetimibe 10 mg daily for 4 to 6 weeks
Other Names:
|
Placebo Comparator: 2
placebo for 4-6 weeks
|
placebo for 4-6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Normalization of resting gallbladder volume in patients with chronic acalculous cholecystitis
Time Frame: Approximately 6 weeks after treatment
|
Approximately 6 weeks after treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Henry A. Pitt, MD, Indiana University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0710-24
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Acalculous Cholecystitis
-
The University of Texas Health Science Center at...CompletedAcute Cholecystitis | Chronic CholecystitisUnited States
-
Ain Shams UniversityCompletedCholecystitis | Chronic Calculous Cholecystitis | Acute Calculous CholecystitisEgypt
-
The University of Texas Health Science Center at...CompletedCholecystitis, Acute | Cholecystitis, ChronicUnited States
-
Medipol UniversityRecruitingCholecystitis, Acute | Cholecystitis | Cholecystitis, ChronicTurkey
-
Medipol UniversityCompletedCholecystitis, Acute | Cholecystitis | Cholecystitis, ChronicTurkey
-
Ministry of Health, MontenegroMedical School of Podgorica, Montenegro; General Hospital Berane, MontenegroCompletedChronic Calculous CholecystitisMontenegro
-
Ewha Womans University Mokdong HospitalUnknownCholecystitis, Acute | Cholecystitis, ChronicKorea, Republic of
-
Samsun Education and Research HospitalCompletedAcute Cholecystitis With Chronic CholecystitisTurkey
-
Cheju Halla General HospitalCompletedAcute Calculous Cholecystitis | Acute Acalculous CholecystitisKorea, Republic of
-
ClinAmygateAswan University HospitalRecruitingCholecystolithiasis | Cholecystitis; Gallstone | Cholecystitis, ChronicEgypt
Clinical Trials on ezetimibe
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Bronx VA Medical CenterCompletedHypercholesterolemiaUnited States
-
Cao YuRecruiting
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Karo Bio ABCompleted
-
Korea UniversityWithdrawn
-
GlaxoSmithKlineCompleted